Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01347645
Recruitment Status : Completed
First Posted : May 4, 2011
Last Update Posted : August 28, 2017
PharmaBio Development Inc.
Information provided by (Responsible Party):
Eisai Inc.

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : June 22, 2015
  Actual Study Completion Date : June 22, 2016